Sat, Aug 30, 2014, 7:37 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • ametrosixual ametrosixual Jul 11, 2013 11:44 AM Flag

    Form 4 FMR LLC Sells Another 42,825 July 9th @ $9.97

     

    and 150,000 common shares under $10.00 since july 5th. clearly this owner is liquidating the common.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • that is a lot of shares....

    • No kneed to lye
      .manee Instities selling .Only reesun you hear from Fidellity is da gotts say.
      Mos everd body else can dump quietly.

    • Just curious. Why are they selling? Have they stated a logical reason?

      • 1 Reply to reggieflautino
      • Best guess is that they heard something which lead them to believe the Phase III results would have a detrimental effect on the share price - and put in place a structured profit-taking program designed to protect them against any accusation of insider trading.

        Here are some details. There have been so sales of shares from the other two holdings for which FMR has beneficial ownership -

        In March this year FMR declared beneficial ownership of 4,700,346 shares.

        1,881,752 shares were owned by FMR's Beacon Bioventures subsidiaries. At some point the ultimate general partner then changed from Fidelity Biosciences Corp to Northern Neck Investors LLC, owned by a group of FMR-related individuals. It seems a fair assumption that the change was directly related to the share selling program which commenced in June.

        Total sales of 921,781 have since been reported - 48.99% of the shares for which Northern Neck assumed control. Last we knew, FMR was still beneficial owner of 3,778,565 shares.

    • good for us...because they are finding buyers at historically high prices...tells us this has
      some real interest behind it...will go much higher.

      • 3 Replies to zake1
      • My guess is that the market makers are starting to fill orders from new institutional buyers. You can watch and see how they pin the price down with hundreds of 100 share trades and skim some here and there. And, shorts are actually doing a little covering - about 65,000 shares or so today. Unless we see new information from the company we may see this sit in a range until the mms have finished what they're doing. Ig we get a big pr release all bets are off.

        Sentiment: Buy

      • Well Zake - if you think these are "historically high prices", you may also know that yesterday CEO Will Lewis when mentioning the rights sold iplex to Shire - would not even mention the drug by name, simply calling iplex a "a historical product we are no longer pursing" - Will Lewis CEO.
        There are no "paid bashers or bad shorts" or boogie men. Insmed is a company with added risks in the last week and until I hear different will invest of facts not heresay There remains selling pressure.

      • What you would had said if they added more shares? Go back last year and read them, and then you may see how stupid you and many other longs sound. Try to be consistent and not always pump. In reality FMR buying shares or selling have almost no material long term stock price impact. So no need to pump when someone gets million shares, and no need to worry when they sell either.

        If Arikace get approval one for for NTM then stock will be a lot higher, until then lots of and lots of noise. Can go up to $20 or $3 before NTM approval.

    • mdplanet@ymail.com mdplanet Jul 11, 2013 2:13 PM Flag

      Um...old news. Same Form 4 we saw earlier in the week. Nothing new here.

    • WOW Looks like they sold too low wouldn't you think???????

 
INSM
13.93+0.11(+0.80%)Aug 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.